SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories trades in the green on the BSE

30 Sep 2013 Evaluate

Ranbaxy Laboratories is currently trading at Rs 334.40, up by 0.45 points or 0.13% from its previous closing of Rs 333.95 on the BSE.

The scrip opened at Rs 336.10 and has touched a high and low of Rs 337.85 and Rs 331.65 respectively. So far 132916 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 559.80 on 08-Nov-2012 and a 52 week low of Rs 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs 345.65 and Rs 326.65 respectively. The current market cap of the company is Rs 14204.46 crore.

The promoters holding in the company stood at 63.51% while Institutions and Non-Institutions held 20.74% and 13.69% respectively.

Credit rating agency, ICRA has assigned ‘A1+’ rating to Ranbaxy Laboratories’ Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs 800 crore. Earlier CP/STD programme of the company for Rs 1,200 crore was also assigned the same rating.

Instruments with these rating are considered to have very strong degree of safety regarding timely payment of financial obligations. Such instruments carry lowest credit risk.

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×